Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, will participate in the Leerink Partners Therapeutics Forum.

Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, will participate in the Leerink Partners Therapeutics Forum.

Management plans to host one-on-one investor meetings on July 15, 2026, in Boston.

Argus Jul 7 session 2 alerts

-3.56% close to close 0.2x rel. volume Open Argus

Details

Market reaction after conference participation: AVTX -3.56% in the Jul 7 session

$1.05B Market Cap

In the Jul 7 session, AVTX declined 3.56%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The key takeaway is simply Avalo’s plan for one-on-one investor meetings at the Leerink forum on Jul...

Analysis

The key takeaway is simply Avalo’s plan for one-on-one investor meetings at the Leerink forum on July 15, 2026; against a backdrop of prior financing, an effective shelf, and elevated short interest, investors may watch for any subsequent pipeline or data disclosures.

Key Figures

Conference date: July 15, 2026

Conference date

July 15, 2026

Leerink Partners Therapeutics Forum in Boston

Historical Context

5 past events · Latest: Jun 26

5 events

1. Jun 26

   Index inclusion news

   24h Move

   +1.1%

   Added to Russell 2000 and 3000 indexes, boosting index investor exposure.

2. Jun 23

   Board appointment

   24h Move

   +4.4%

   Added experienced biopharma executive to board following positive trial data.

3. Jun 16

   Pipeline expansion

   24h Move

   -1.9%

   Advanced AVTX-010 next-generation anti-IL-1β antibody toward IND filing.

4. May 22

   Inducement option grant

   24h Move

   -2.0%

   Granted stock option inducement award to new employee under Nasdaq rule.

5. May 13

   Q1 results update

   24h Move

   -0.5%

   Reported Q1 2026 loss alongside financing and positive Phase 2 LOTUS data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.

For media and investor inquiries

Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Avalo Therapeutics (AVTX) attend the Leerink Partners Therapeutics Forum in 2026?

Avalo Therapeutics will participate in the Leerink Partners Therapeutics Forum on July 15, 2026. According to Avalo Therapeutics, management will host one-on-one investor meetings during the event in Boston to engage with current and potential shareholders.

What is Avalo Therapeutics (AVTX) planning to do at the 2026 Leerink Partners Therapeutics Forum?

Avalo Therapeutics plans to host one-on-one investor meetings at the 2026 Leerink Partners Therapeutics Forum. According to Avalo Therapeutics, these meetings will allow management to discuss the company’s IL-1β pathway-focused pipeline and strategy with institutional investors in Boston.

Where will Avalo Therapeutics (AVTX) hold investor meetings during the July 15, 2026 forum?

Avalo Therapeutics will hold investor meetings in Boston during the July 15, 2026 Leerink Partners Therapeutics Forum. According to Avalo Therapeutics, management will conduct one-on-one sessions with investors to provide corporate and pipeline updates on its immune-mediated inflammatory disease programs.

What type of company is Avalo Therapeutics (AVTX) participating in the 2026 Leerink forum?

Avalo Therapeutics is a clinical-stage biotechnology company focused on IL-1β pathway therapeutics. According to Avalo Therapeutics, the company is fully dedicated to developing treatments for immune-mediated inflammatory diseases and will discuss this strategy during investor meetings at the Leerink Partners Therapeutics Forum.

Why might Avalo Therapeutics (AVTX) investor meetings at the Leerink forum matter to shareholders?

The investor meetings may help increase awareness of Avalo Therapeutics’ strategy and pipeline among institutional investors. According to Avalo Therapeutics, hosting one-on-one meetings in Boston offers a platform to communicate its IL-1β pathway focus and clinical-stage programs to the investment community.